3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Carcinoma, Hepatocellular
59
Cholangiocarcinoma
19
Carcinoma, Renal Cell
16
Biliary Tract Neoplasms
11
Stomach Neoplasms
9
Thyroid Neoplasms
8
Endometrial Neoplasms
8
Parkinson Disease 4, Autosomal Dominant Lewy Body
7
Neoplasms
7
Melanoma
6
Uterine Cervical Neoplasms
5
Thyroid Carcinoma, Anaplastic
5
Neuroendocrine Tumors
5
Carcinoma, Non-Small-Cell Lung
5
Recurrence
4
Ovarian Neoplasms
4
Liver Neoplasms
4
Thyroid Cancer, Papillary
3
Squamous Cell Carcinoma of Head and Neck
3
Small Cell Lung Carcinoma
3
Neoplasm Metastasis
3
Cirrhosis, Familial, with Pulmonary Hypertension
3
Brain Neoplasms
3
Advanced Biliary Tract Cancer
3
Adenocarcinoma, Follicular
3
Vulvar Neoplasms
2
Uveal Melanoma
2
Triple Negative Breast Neoplasms
2
Thymoma
2
Solid Tumors
2
Interventions
Gemcitabine
83
Cisplatin
59
pembrolizumab
28
Paclitaxel
21
Nivolumab
21
Carboplatin
21
Cystectomy
20
Docetaxel
18
durvalumab
17
atezolizumab
17
Magnetic Resonance Spectroscopy
16
Specimen Handling
15
Radiotherapy
14
avelumab
13
Mitomycin
13
Sunitinib
12
Doxorubicin
12
Methotrexate
11
Fluorouracil
11
Vinblastine
10
Filgrastim
7
BCG Vaccine
7
Sorafenib
6
Ipilimumab
6
Immunoglobulin G
6
Disulfides
6
Biopsy
6
enfortumab vedotin
5
cabozantinib
5
Trastuzumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Urinary Bladder Neoplasms
×
lenvatinib
×
Clear all
NCT05007106
2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2
Completed
613 enrolled